In particular, the ongoing CARMAN study [41] including brexucabtagene autoleucel following a shortened induction with chemo‐immunotherapy plus BTKi compared to standard of care, is enrolling MCL patients with MIPI‐c high‐intermediate or high risk and/or TP53 mutation and/or p53 overexpression by immunohistochemistry. Here, TP53 is linked to mantle cell lymphoma.